{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:09:35Z","timestamp":1779376175145,"version":"3.53.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Sanjiu Brain Hospital","award":["No. B392024005"],"award-info":[{"award-number":["No. B392024005"]}]},{"name":"Guangdong Sanjiu Brain Hospital","award":["No. A392024009"],"award-info":[{"award-number":["No. A392024009"]}]},{"name":"Guangdong Sanjiu Brain Hospital","award":["No. A392024002"],"award-info":[{"award-number":["No. A392024002"]}]},{"name":"Guangdong Sanjiu Brain Hospital","award":["No. C392024021"],"award-info":[{"award-number":["No. C392024021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11060-025-05045-6","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:09:19Z","timestamp":1750216159000},"page":"471-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis"],"prefix":"10.1007","volume":"174","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"5045_CR1","doi-asserted-by":"publisher","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer, lung cancer (Amsterdam, Netherlands). 86:78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020","DOI":"10.1016\/j.lungcan.2014.07.020"},{"key":"5045_CR2","doi-asserted-by":"publisher","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB (2015) Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers, lung cancer (Amsterdam, Netherlands). 88:108\u2013111. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.020","DOI":"10.1016\/j.lungcan.2015.01.020"},{"key":"5045_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","volume":"96","author":"F Hsu","year":"2016","unstructured":"Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C (2016) EGFR mutation status on brain metastases from non-small cell lung cancer. Lung cancer (Amsterdam Netherlands) 96:101\u2013107. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.004","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"5045_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/jto.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH (2014) EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 9:195\u2013199. https:\/\/doi.org\/10.1097\/jto.0000000000000069","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"5045_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/s1470-2045(11)70184-x","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, the lancet. Oncology 12:735\u2013742. https:\/\/doi.org\/10.1016\/s1470-2045(11)70184-x","journal-title":"Oncology"},{"key":"5045_CR6","doi-asserted-by":"publisher","unstructured":"Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, Macerelli M, Polo V, Pilotto S, Santarpia M, Cumerlato E, Da Ros V, Targato G, Bortolami A, Bonanno L, Ferro A, Dal Maso A, Frega S, Guarneri V (2024) Osimertinib in patients with Treatment-Naive EGFR-Mutant Non-small cell lung cancer: overall survival, Post-progression management and budget impact analysis in Real-World, the oncologist. 29:596\u2013608. https:\/\/doi.org\/10.1093\/oncolo\/oyae043","DOI":"10.1093\/oncolo\/oyae043"},{"key":"5045_CR7","doi-asserted-by":"publisher","unstructured":"Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A, Pilotto S, Polo V, Santarpia M, Chiari R, Pavan A, Dal Maso A, Da Ros V, Targato G, Vari S, Indraccolo S, Calabrese F, Frega S, Bonanno L, Conte PF, Guarneri V, Pasello G (2022) First-Line osimertinib in patients with EGFR-Mutant advanced Non-Small cell lung cancer: outcome and safety in the real world: FLOWER study, the oncologist. 27:87\u2013e. https:\/\/doi.org\/10.1002\/onco.13951","DOI":"10.1002\/onco.13951"},{"key":"5045_CR8","doi-asserted-by":"publisher","unstructured":"Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF (2015) Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis, lung cancer (Amsterdam, Netherlands). 89:255\u2013261. https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.023","DOI":"10.1016\/j.lungcan.2015.05.023"},{"key":"5045_CR9","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Yan HH, Wu YL (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 11:1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"5045_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3171\/2022.11.Jns221888","volume":"139","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Yang HC, Luo YH, Chen CJ, Wu HM, Chen YM, Hu YS, Lin CJ, Chung WY, Shiau CY, Guo WY, Chou TY, Pan DH, Lee CC (2023) Leptomeningeal metastasis in patients with non-small cell lung cancer after stereotactic radiosurgery for brain metastasis. J Neurosurg 139:385\u2013392. https:\/\/doi.org\/10.3171\/2022.11.Jns221888","journal-title":"J Neurosurg"},{"key":"5045_CR11","doi-asserted-by":"publisher","unstructured":"Le Rhun E, Weller M, van den Bent M, Brandsma D, Furtner J, Rud\u00e0 R, Schadendorf D, Seoane J, Tonn JC, Wesseling P, Wick W, Minniti G, Peters S, Curigliano G, Preusser M (2023) Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 8. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101624","DOI":"10.1016\/j.esmoop.2023.101624"},{"key":"5045_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/jco.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ (2020) Osimertinib in patients with epidermal growth factor receptor Mutation-Positive Non-Small-Cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncology: Official J Am Soc Clin Oncol 38:538\u2013547. https:\/\/doi.org\/10.1200\/jco.19.00457","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5045_CR13","doi-asserted-by":"publisher","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD (2018) Consolidative radiotherapy for limited metastatic Non-Small-Cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol 4. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","DOI":"10.1001\/jamaoncol.2017.3501"},{"key":"5045_CR14","doi-asserted-by":"crossref","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet (London England) 403:171\u2013182. https:\/\/doi.org\/10.1016\/s0140-6736(23)01857-3","DOI":"10.1016\/S0140-6736(23)01857-3"},{"key":"5045_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-022-00878-x","volume":"17","author":"YH Huang","year":"2022","unstructured":"Huang YH, Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Chang GC (2022) The difference in clinical outcomes between osimertinib and Afatinib for First-Line treatment in patients with advanced and recurrent EGFR-Mutant Non-Small cell lung cancer in Taiwan. Target Oncol 17:295\u2013306. https:\/\/doi.org\/10.1007\/s11523-022-00878-x","journal-title":"Target Oncol"},{"key":"5045_CR16","doi-asserted-by":"crossref","unstructured":"Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M (2023) Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Translational Lung cancer Res 12:2229\u20132244. https:\/\/doi.org\/10.2103","DOI":"10.21037\/tlcr-23-577"},{"key":"5045_CR17","doi-asserted-by":"crossref","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varn\u00e4s K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, Vazquez-Romero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE (2021) Preclinical comparison of the Blood-brain barrier permeability of osimertinib with other EGFR TKIs, clinical cancer research: an official journal of the American association for cancer research. 27:189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1871","DOI":"10.1158\/1078-0432.CCR-19-1871"},{"key":"5045_CR18","doi-asserted-by":"publisher","unstructured":"Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL, Yang JC (2023) Osimertinib for EGFR-Mutant Non-Small-Cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies, targeted oncology. 18:9\u201324. https:\/\/doi.org\/10.1007\/s11523-022-00941-7","DOI":"10.1007\/s11523-022-00941-7"},{"key":"5045_CR19","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang Y, Niu W, Ge X, Huang F, Pang J, Li X, Wang Y, Gao W, Fan F, Li S, Liu H (2021) Experimental study of almonertinib crossing the Blood-Brain barrier in EGFR-Mutant NSCLC brain metastasis and spinal cord metastasis models, frontiers in Pharmacology. 12:750031. https:\/\/doi.org\/10.3389\/fphar.2021.750031","DOI":"10.3389\/fphar.2021.750031"},{"key":"5045_CR20","doi-asserted-by":"crossref","unstructured":"Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q (2022) A randomized phase III trial of aumolertinib versus gefitinib as First-Line therapy for locally advanced or MetastaticNon-Small-Cell lung cancer with EGFR exon 19 deletion or L858R mutations, journal of clinical oncology, vol 40. official journal of the American Society of Clinical Oncology, AENEAS, pp 3162\u20133171. https:\/\/doi.org\/10.1200\/jco.21.02641","DOI":"10.1200\/JCO.21.02641"},{"key":"5045_CR21","doi-asserted-by":"publisher","unstructured":"Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Weng J, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Wei H, Wei J, Zhang Z, Wu Q (2024) Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS). Cancer communications (London, England) https:\/\/doi.org\/10.1002\/cac2.12594","DOI":"10.1002\/cac2.12594"},{"key":"5045_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C (2022) Central nervous system efficacy of Furmonertinib (AST2818) versus gefitinib as First-Line treatment for EGFR-Mutated NSCLC: results from the FURLONG study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 17:1297\u20131305. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.1143","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"5045_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12885-023-10676-x","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu Z, Hao X, Wang Q, Yang K, Li J, Xing P (2023) Intracranial efficacy and safety of Furmonertinib 160\u00a0mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer 23:206. https:\/\/doi.org\/10.1186\/s12885-023-10676-x","journal-title":"BMC Cancer"},{"key":"5045_CR24","doi-asserted-by":"publisher","unstructured":"Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M (2024) Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small cell lung cancer, lung cancer (Amsterdam, Netherlands). 191. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107540","DOI":"10.1016\/j.lungcan.2024.107540"},{"key":"5045_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.05.125","volume":"111","author":"F Yu","year":"2021","unstructured":"Yu F, Ni J, Zeng W, Zhou Y, Guo T, Zeng Y, Zhao Y, Li S, Li Y, Yang X, Zou L, Wang S, Liu Q, Li Y, Chu L, Chu X, Ye L, Yu W, Zhu Z (2021) Clinical value of upfront cranial radiation therapy in Osimertinib-Treated epidermal growth factor Receptor\u2013Mutant Non-Small cell lung cancer with brain metastases. Int J Radiation Oncology*Biology*Physics 111:804\u2013815. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.125","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"5045_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3171\/jns\/2008\/108\/2\/0248","volume":"108","author":"D Suki","year":"2008","unstructured":"Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD (2008) Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108:248\u2013257. https:\/\/doi.org\/10.3171\/jns\/2008\/108\/2\/0248","journal-title":"J Neurosurg"},{"key":"5045_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jocn.2017.12.009","volume":"49","author":"PM Foreman","year":"2018","unstructured":"Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie BL, Fisher WS, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB (2018) Postoperative radiosurgery for the treatment of metastatic brain tumor: evaluation of local failure and leptomeningeal disease. J Clin Neuroscience: Official J Neurosurgical Soc Australasia 49:48\u201355. https:\/\/doi.org\/10.1016\/j.jocn.2017.12.009","journal-title":"J Clin Neuroscience: Official J Neurosurgical Soc Australasia"},{"key":"5045_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ijrobp.2021.05.124","volume":"111","author":"RS Prabhu","year":"2021","unstructured":"Prabhu RS, Dhakal R, Vaslow ZK, Dan T, Mishra MV, Murphy ES, Patel TR, Asher AL, Yang K, Manning MA, Stern JD, Patel AR, Wardak Z, Woodworth GF, Chao ST, Mohammadi A, Burri SH (2021) Preoperative radiosurgery for resected brain metastases: the PROPS-BM multicenter cohort study. Int J Radiat Oncol Biol Phys 111:764\u2013772. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.124","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5045_CR29","doi-asserted-by":"publisher","unstructured":"Fitzpatrick A, Iravani M, Mills A, Childs L, Alaguthurai T, Clifford A, Garcia-Murillas I, Van Laere S, Dirix L, Harries M, Okines A, Turner NC, Haider S, Tutt ANJ, Isacke CM (2022) Assessing CSF ctdna to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis, clinical cancer research: an official journal of the American association for cancer research. 28:1180\u20131191. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3017","DOI":"10.1158\/1078-0432.Ccr-21-3017"},{"key":"5045_CR30","doi-asserted-by":"publisher","unstructured":"Wang Y, Yang X, Li NJ, Xue JX (2022) Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment, lung cancer (Amsterdam, Netherlands). 174:1\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.013","DOI":"10.1016\/j.lungcan.2022.09.013"},{"key":"5045_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11060-021-03827-2","volume":"154","author":"ED Bander","year":"2021","unstructured":"Bander ED, Yuan M, Reiner AS, Garton ALA, Panageas KS, Brennan CW, Tabar V, Moss NS (2021) Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. J Neurooncol 154:301\u2013313. https:\/\/doi.org\/10.1007\/s11060-021-03827-2","journal-title":"J Neurooncol"},{"key":"5045_CR32","doi-asserted-by":"publisher","unstructured":"Woo B, Gwak HS, Kwon JW, Shin SH, Yoo H (2022) Lumboperitoneal shunt combined with Ommaya reservoir enables continued intraventricular chemotherapy for leptomeningeal metastasis with increased intracranial pressure, brain tumor research and treatment. 10:237\u2013243. https:\/\/doi.org\/10.14791\/btrt.2022.0022","DOI":"10.14791\/btrt.2022.0022"},{"key":"5045_CR33","doi-asserted-by":"publisher","unstructured":"Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, Chari A, Hill CS, Thorne L (2023) Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis. NeuroSurg Focus 55. https:\/\/doi.org\/10.3171\/2023.5.Focus23195","DOI":"10.3171\/2023.5.Focus23195"},{"key":"5045_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","volume":"20","author":"H Chen","year":"2025","unstructured":"Chen H, Yang S, Wang L, Wu Y, Wu Y, Ma S, He Z, Zhang C, Liu Y, Tang H, Dong H, Wang Q (2025) High-Dose Furmonertinib in patients with EGFR-Mutated NSCLC and leptomeningeal metastases: A prospective Real-World study. J Thorac Oncol 20:65\u201375. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1385","journal-title":"J Thorac Oncol"},{"key":"5045_CR35","doi-asserted-by":"publisher","unstructured":"Li M, Chen J, Zhang B, Yu J, Wang N, Li D, Shao Y, Zhu D, Liang C, Ma Y, Ou Q, Hou X, Chen L (2022) Dynamic monitoring of cerebrospinal fluid Circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028), BMC medicine. 20:398. https:\/\/doi.org\/10.1186\/s12916-022-02595-8","DOI":"10.1186\/s12916-022-02595-8"},{"key":"5045_CR36","doi-asserted-by":"publisher","first-page":"17731","DOI":"10.1002\/cam4.6393","volume":"12","author":"T Tozuka","year":"2023","unstructured":"Tozuka T, Noro R, Miyanaga A, Nakamichi S, Takeuchi S, Matsumoto M, Kubota K, Kasahara K, Seike M (2023) Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer. Cancer Med 12:17731\u201317739. https:\/\/doi.org\/10.1002\/cam4.6393","journal-title":"Cancer Med"},{"key":"5045_CR37","doi-asserted-by":"crossref","unstructured":"Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazi\u00e8res J, Curcio H, Was\u0105g B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R (2024) Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-Mutant Non-Small-Cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol 42:1350\u20131356. https:\/\/doi.org\/10.1200\/jco.23.01521","DOI":"10.1200\/JCO.23.01521"},{"key":"5045_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-Mutated advanced Non-Small-Cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2018.78.3118","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"5045_CR39","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1002\/cam4.2156","volume":"8","author":"W Yan","year":"2019","unstructured":"Yan W, Jing W, An N, Tian Y, Guo D, Kong L, Zhu H, Yu J (2019) The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer Institute. Cancer Med 8:2769\u20132776. https:\/\/doi.org\/10.1002\/cam4.2156","journal-title":"Cancer Med"},{"key":"5045_CR40","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1038\/s41598-025-91863-7","volume":"15","author":"R Lu","year":"2025","unstructured":"Lu R, Wang Z, Tian W, Shi W, Chu X, Zhou R (2025) A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer. Sci Rep 15:7036. https:\/\/doi.org\/10.1038\/s41598-025-91863-7","journal-title":"Sci Rep"},{"key":"5045_CR41","doi-asserted-by":"crossref","unstructured":"Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, Chu X, Yu F, Zeng Y, Guo T, Zhou Y, Zou L, Li Y, Ni J, Zhu Z (2022) Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. Int J Cancer 150:1318\u20131328. https:\/\/doi.org\/10.1002\/ijc.33904","DOI":"10.1002\/ijc.33904"},{"key":"5045_CR42","doi-asserted-by":"publisher","unstructured":"Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW (2019) Osimertinib for EGFR-Mutant lung cancer with brain metastases: results from a Single-Center retrospective study, the oncologist, 24. 836\u2013843. https:\/\/doi.org\/10.1634\/theoncologist.2018-0264","DOI":"10.1634\/theoncologist.2018-0264"},{"key":"5045_CR43","doi-asserted-by":"publisher","unstructured":"Helis CA, Hughes RT, Glenn CW, Lanier CM, Masters AH, Dohm A, Ahmed T, Ruiz J, Triozzi P, Gondal H, Cramer CK, Tatter SB, Laxton AW, Xing F, Lo HW, Su J, Watabe K, Wang G, Whitlow CT, Chan MD (2020) Predictors of adverse radiation effect in brain metastasis patients treated with stereotactic radiosurgery and immune checkpoint inhibitor therapy. Int J Radiat Oncol Biol Phys 108:295\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.057","DOI":"10.1016\/j.ijrobp.2020.06.057"},{"key":"5045_CR44","doi-asserted-by":"publisher","unstructured":"Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial, the lancet. Oncology 18:1049\u20131060. https:\/\/doi.org\/10.1016\/s1470-2045(17)30441-2","DOI":"10.1016\/s1470-2045(17)30441-2"},{"key":"5045_CR45","doi-asserted-by":"publisher","first-page":"109744","DOI":"10.1016\/j.radonc.2023.109744","volume":"186","author":"R Bodensohn","year":"2023","unstructured":"Bodensohn R, Kaempfel AL, Boulesteix AL, Orzelek AM, Corradini S, Fleischmann DF, Forbrig R, Garny S, Hadi I, Hofmaier J, Minniti G, Mansmann U, Pazos Escudero M, Thon N, Belka C, Niyazi M (2023) Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4\u201310 brain metastases: A nonrandomized controlled trial. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol 186:109744. https:\/\/doi.org\/10.1016\/j.radonc.2023.109744","journal-title":"Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol"},{"key":"5045_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12094-022-02927-3","volume":"25","author":"S Yao","year":"2023","unstructured":"Yao S, Zuo H, Li W, Cai Y, Zhang Q, Pang L, Jing Y, Yin X, Cheng H (2023) The correlations between psychological distress, cognitive impairment and quality of life in patients with brain metastases after whole-brain radiotherapy. Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico 25:207\u2013217. https:\/\/doi.org\/10.1007\/s12094-022-02927-3","journal-title":"Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"5045_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","volume":"15","author":"J Zhen","year":"2020","unstructured":"Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, Lin T, Wu J, Wang W, Xu S, Liu D, Lu M, Zhu D, Chen L, Cai L, Zhou C (2020) Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiation Oncol (London England) 15:185. https:\/\/doi.org\/10.1186\/s13014-020-01627-y","journal-title":"Radiation Oncol (London England)"},{"key":"5045_CR48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncology: Official Publication Int Association Study Lung Cancer 7:382\u2013385. https:\/\/doi.org\/10.1097\/JTO.0b013e3182398e4f","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"5045_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ijrobp.2019.02.051","volume":"104","author":"E Miyawaki","year":"2019","unstructured":"Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T (2019) Optimal sequence of local and EGFR-TKI therapy for EGFR-Mutant Non-Small cell lung cancer with brain metastases stratified by number of brain metastases. Int J Radiation Oncology*Biology*Physics 104:604\u2013613. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.051","journal-title":"Int J Radiation Oncology*Biology*Physics"}],"updated-by":[{"DOI":"10.1007\/s11060-025-05404-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05045-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05045-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:17:27Z","timestamp":1768342647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05045-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05045-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11060-025-05404-3","URL":"https:\/\/doi.org\/10.1007\/s11060-025-05404-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of the Guangdong Sanjiu Brain Hospital (No.2024-01-019), and there was informed consent exemption for all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}